Q1 2019 Trends in Medtech Transactions Report
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2019 Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the life sciences deal landscape.
In this report you can find an overview and analysis of the following medtech activities:
- Key performance indicators for the medtech market
- IPO and private financing activity and performance
- Deal activity for M&A
- A look ahead and our predictions of the future
HERE’S A SUMMARY OF KEY FINDINGS:
Q1 M&A activity represents a trend towards orthopedics and robotics
- M&A activity in Q1 focused on developing newer areas crucial to ongoing growth and health of the orthopedics and robotics sectors
- Robotics, planning software, digital surgery, biodegradable implants, and non-drug, non-surgical treatments for pain draw the majority of the M&A and financing activity
Capital from a broad spectrum of investors is supporting development and commercialization of surgical and diagnostic medical technologies
Medtech markets end Q1 at a high, with the industry demonstrating positive divergence from the S&P
Activities in digital health in Q1 indicate a rise of global medical technology
- FDA piloting pre-cert program to allow developers who have been assessed by the FDA for meeting specific excellence principles to participate in a more tailored premarket submission process for their specific digital device
- The global orthopedist device market was valued at $38.7B in 2017, and is expected to reach $49.8B by the end of 2022
- Despite the threat of cybersecurity issues related to digital technologies, investment by healthcare organizations in the space continues to grow